Komori
Pharmarise Holdings (2796) · TargetAdvancedLatest Management plan (2026-09-17): "Restated"

GHG Emissions Reduction and the 2050 Carbon Neutrality Target

First written in FY2024. 2 of 4 entries say "Advanced", first in FY2025. Latest entry: 2026-09-17.

4entries
3years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024AdvancedFY2025 – FY20262024: 120242025: 120252026: 22026
Same theme, other companies
GHG emissions (Scopes 1–3): calculation, emissions-reduction target-setting and renewable energy procurementA theme 999 companies write about · 7 as a headwind · 1055 as a tailwind

28 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 191 companies compared. The sentences above are computed from all 191.Comparing 200 of the theme's 1063 threads.
Full recordFilings, disclosures and news, newest first
  1. 2026-09-17RestatedManagement plan

    「CO2 emissions reduction / 30% reduction from fiscal 2022 (fiscal 2030 target)」

    The target of reducing CO2 emissions in fiscal 2030 by 30% from fiscal 2022 was continued under the new materiality framework.
  2. FY2026AdvancedAnnual report

    「The Group's greenhouse gas emissions (total Scope 1 and Scope 2) were 5,924t-CO2e as of fiscal 2025 (the fiscal year ending May 2026). For fiscal 2030, the reduction target is to reduce emissions per ¥100 million of revenue by 30% from fiscal 2022 levels.」

    Fiscal 2025 actual GHG emissions of 5,924t-CO2e and emissions of 8.5t-CO2e per ¥100 million of revenue were disclosed, together with targets of 6.7t-CO2e in 2030 and net zero in 2050.
  3. FY2025AdvancedAnnual report

    「At present, the Company envisages an interim GHG reduction target of reducing GHG emissions in 2030 by 30% from 2022 levels, with the ultimate goal of achieving carbon neutrality in 2050.」

    Scope 1 and 2 GHG emissions totaling 6,780t-CO2e were disclosed, together with indicators of 6.7t-CO2e per ¥100 million of revenue in 2030 and net zero in 2050.
  4. FY2024First statedAnnual report

    「At present, the Company envisages an interim GHG reduction target of reducing GHG emissions in 2030 by 30% from 2022 levels, with the ultimate goal of achieving carbon neutrality in 2050.」

    For Scope 1 and Scope 2, the Company presented for the first time an interim target of reducing emissions by 30% from 2022 levels by 2030 and achieving carbon neutrality by 2050. Total Scope 1 and 2 emissions in fiscal 2023 were 4,868t-CO2e.
Moved together

"Expanding Scale and Store Network through M&A and New Store Openings" moved the same way as this thread, in the same document, in 2 of its 4 moves.

222222★123456
  1. ★This thread
  2. 1Expanding Scale and Store Network through M&A and New Store Openings2×
  3. 2Establishing a Sustainability Committee and Strengthening ESG Initiatives2×
  4. 3Fiscal Year Ending May 2026 Targets for Workforce Diversity, Parental Leave and the Gender Pay Gap2×
  5. 4Nationwide Dispensing-Pharmacy Store Network2×
  6. 5Recruiting and Developing Pharmacists and Other Personnel2×
  7. 6Unprofitable Stores and the Risk of Impairment of Fixed Assets2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Pharmarise Holdings's next results are scheduled for 2026-09-17. Read the earnings preview It last moved in the Management plan of 2026-09-17: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
GHG Emissions Reduction and the 2050 Carbon Neutrality Target | Pharmarise Holdings Corporation (2796) | Komori